Genfit is a late-stage clinical biopharmaceutical company dedicated to the discovery and development of drug candidates and diagnostic solutions targeting metabolic and liver-related diseases. Co. is engaged in the field of nuclear receptor-based drug discovery. Co. is evaluating its drug candidate, elafibranor, in a Phase 3 clinical trial as a potential treatment for nonalcoholic steatohepatitis, and as a potential treatment for primary biliary cholangitis. Co. is also developing a clinical-stage program based on drug repositioning to develop an anti-fibrotic drug. Co.'s primary drug candidate in this program, nitazoxanide, is an approved anti-parasitic agent. The GNFT stock yearly return is shown above.
The yearly return on the GNFT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GNFT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|